Yahoo Web Search

  1. Ads
    related to MERCK & CO., INC
  1. Intellia Therapeutics, Inc. (NTLA) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 01 16:23 PM

    John Leonard -- President and Chief Executive Officer Yeah. We don't give many details, but for the purposes of the tox work and getting in the clinical, it's a collection of different suppliers ...

  2. Moleculin Completes Enrollment in Early-Stage Cancer Study

    Zacks via Yahoo FinanceAug 15 11:55 AM

    Moleculin Biotech, Inc. MBRX announced that it has completed enrollment in the proof-of-concept clinical study evaluating its p-STAT3 inhibitor candidate, WP1220...skin cancer. The company ...

  3. Buy 5 Dow Stocks That Have Surged Despite Market Gyrations

    Zacks via Yahoo FinanceAug 19 12:49 PM

    Wall Street started 2019 with a lot of vigor, quickly erasing the loss it suffered in 2018. After an impressive bull run in the first four months, volatility has once again reared its ugly face ...

  4. Agenus Inc (AGEN) Q2 2019 Earnings Call Transcript

    Motley Fool via Yahoo FinanceAug 10 5:43 AM

    Thank you for standing by and welcome to the Agenus Second Quarter 2019 Conference Call. In the first half of 2019, we have continued to deliver new discoveries to the clinic, and advance our ...

  5. In a separate press release, AstraZeneca announced that the phase III study (PAOLA-1) evaluating its and Merck's MRK PARP inhibitor, Lynparza, for a broader advanced ovarian cancer patient ...

  6. Apple Inc's results after markets close illuminate the impact of trade tensions with China.

  7. Here's Why Procter & Gamble is a Hot Investment Pick Now

    Zacks via Yahoo FinanceAug 12 13:03 PM

    The Procter & Gamble Company PG, popularly known as P&G, appears to be a solid bet driven by continued investments to aid business growth. Moreover, it remains focused on product improvement ...

  8. PD-L1 inhibitors available on the market are Merck’s MRK Keytruda, AstraZeneca’s AZN Imfinzi, Bristol Myers’ BMY Opdivo, Roche’s Tecentriq and Pfizer’s PFE Bavencio. ...

  9. This week, the FDA granted approval to Roche's RHHBY tumor-agnostic medicine, Rozlytrek (entrectinib), and J&J's JNJ tuberculosis tablet Sirturo for adolescent patients. Meanwhile, Lilly LLY ...

  10. Roche Holdings RHHBY announced that the FDA has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also ...

  1. Ads
    related to MERCK & CO., INC